论文部分内容阅读
本文报告在去年第20届国际抗微生物制剂和化疗会议(20th ICAAC)上发表的头孢菌素类(Scrip No.529)和β-内酰胺酶抑制剂以外的新抗生素的最新资料。许多值得重视的新的非头孢菌素抗生素的数据今年首次提了出来,并且将连续在《Scrip》上发表。西德本月将氧哌嗪青霉素投放市场有18篇论文证实Lederle实验室的半合成青霉素——氧哌嗪青霉素(Pipril),在治疗肺炎、腹膜炎、心内膜炎、败血症,以及并发的尿道和胆道感染等严重疾病方面的疗效。正如去年会议上所预期的,氧哌嗪青霉素已在瑞士、西德、菲律宾、巴西、意大利
This article reports on the most up-to-date information on new antibiotics other than cephalosporins (Scrip No. 529) and β-lactamase inhibitors, which were published at the 20th ICAAC (International Conference on Antibiotics and Chemotherapy) last year. Many new non-cephalosporin antibiotic data worth highlighting were first introduced this year and will be published consecutively on “Scrip.” West Germany Puts Pipeoxypenamine to Market This Month Eighteen papers confirm that Lederle’s semi-synthetic penicillin, Pipril, is used in the treatment of pneumonia, peritonitis, endocarditis, septicemia, and concurrent urethra And biliary tract infections and other serious diseases. As expected at last year’s meeting, piperacillin is already available in Switzerland, West Germany, the Philippines, Brazil, Italy